ACE and COVID-19: On the other hand, a recent meta-analysis published by Chang Chu et al. concluded that angiotensin-converting enzyme inhibitors (ACEIs) reduce the risk of SARS-CoV-2 infection and all causes of COVID-19 mortality, including the risk of non-COVID-19 pneumonia [16].